Giggles N’ Hugs’ Engages PacificShore Ventures to Explore M&A Opportunities
Apr 24, 2017 12:03 pm UTC| Business
Los Angeles, April 24, 2017 -- Giggles N’ Hugs, Inc. (OTCQB: GIGL), owner and operator of family-friendly restaurants that bring together high-end, organic food with active, cutting-edge play and entertainment for...
Silicon Motion Confirms Quarterly Dividend
Apr 24, 2017 12:02 pm UTC| Business
TAIPEI, Taiwan and MILPITAS, Calif., April 24, 2017 -- Silicon Motion Technology Corporation (NasdaqGS: SIMO)(“Silicon Motion” or the “Company”), a global leader in designing and marketing NAND flash controllers for...
Silicon Motion Confirms Quarterly Dividend
Apr 24, 2017 12:02 pm UTC| Business
TAIPEI, Taiwan and MILPITAS, Calif., April 24, 2017 -- Silicon Motion Technology Corporation (NasdaqGS: SIMO)(“Silicon Motion” or the “Company”), a global leader in designing and marketing NAND flash controllers for...
Silicon Motion Confirms Quarterly Dividend
Apr 24, 2017 12:02 pm UTC| Business
TAIPEI, Taiwan and MILPITAS, Calif., April 24, 2017 -- Silicon Motion Technology Corporation (NasdaqGS: SIMO)(“Silicon Motion” or the “Company”), a global leader in designing and marketing NAND flash controllers for...
Inovio Initiates Phase 2 Efficacy Trial with VGX-3100 For HPV-Related Vulvar Pre-Cancers
Apr 24, 2017 12:02 pm UTC| Business
New study expands VGX-3100 program for evaluating therapeuticapplications in HPV-related pre-cancers with high medical need VGX-3100 previously demonstrated efficacyin regressing HPV-related cervical pre-cancer PLYMOUTH...
Inovio Initiates Phase 2 Efficacy Trial with VGX-3100 For HPV-Related Vulvar Pre-Cancers
Apr 24, 2017 12:02 pm UTC| Business
New study expands VGX-3100 program for evaluating therapeuticapplications in HPV-related pre-cancers with high medical need VGX-3100 previously demonstrated efficacyin regressing HPV-related cervical pre-cancer PLYMOUTH...
Inovio Initiates Phase 2 Efficacy Trial with VGX-3100 For HPV-Related Vulvar Pre-Cancers
Apr 24, 2017 12:02 pm UTC| Business
New study expands VGX-3100 program for evaluating therapeuticapplications in HPV-related pre-cancers with high medical need VGX-3100 previously demonstrated efficacyin regressing HPV-related cervical pre-cancer PLYMOUTH...